HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PEGBIO CO-B

59.450

+3.0505.41%

Volume:231.50K

Turnover:13.64M

Market Cap:22.95B

PE:-70.31

High:60.000

Open:54.750

Low:54.750

Close:56.400

52wk High:62.250

52wk Low:8.680

Shares:386.00M

HK Float Shares:279.16M

Volume Ratio:1.86

T/O Rate:0.08%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.846

ROE:-224.15%

ROA:-61.30%

PB:82.12

PE(LYR):-70.31

PS:-5408.82

Loading ...

Overview Company News Filings

HK Movers | Biomedical Stocks Jump With CStone Pharmaceuticals up 13%

Tiger Newspress

HK Stock Movement | PEGBIO CO-B (02565) Surges Over 15% as GLP-1 Weight-Loss Drug Expands to Middle East and Africa

PegBio (02565) Publishes Monthly Securities Return for October 2025

Bulletin Express

PegBio (2565) Announces Voluntary Dissolution of Shanghai Maiji and Director’s Information Update

Bulletin Express

HK Stock Movement | PEGBIO CO-B (02565) Surges Over 20% at Close to Hit New High, Secures Exclusive License for Diabetes Drug in Middle East & Africa

PegBio Proposes Exclusive License for Diabetes Mellitus Drug for UAE Pharma R&D Firm

MT Newswires Live

BRIEF-PegBio Says PDC Granted Exclusive License For Pb-119 In Middle East And Africa

PEGBIO CO-B (02565): Proposes to Grant Exclusive License for VISEPEGENATIDE (PB-119) in Middle East and Africa

Pegbio Co Ltd Announces Proposed Exclusive License Agreement for Visepegenatide PB119 in Middle East and Africa

Pegbio Co Ltd - Announces Non-Binding Term Sheet With Pdc Fz-Llc

THOMSON REUTERS

Pegbio Co Ltd - Pdc Granted Exclusive License for PB-119 in Middle East and Africa

THOMSON REUTERS

Pegbio Co Ltd - License Includes Regional Development and Commercialization

THOMSON REUTERS

Hong Kong Stock Movement | PEGBIO CO-B (02565) Surges Over 5% in Morning Trading, Advanced Clinical Progress in GLP-1 Multi-Target Field with PB-718 as Key Pipeline Product

PEGBIO CO-B (02565): Major Milestone Breakthrough in MASH Treatment R&D Opens Up Hundred-Billion Valuation Growth Ceiling

Hong Kong Stock Alert | PEGBIO CO-B (02565) Surges Over 7% to New High as PB-119 Registration Application Accepted, Domestic Commercialization Imminent

PegBio Narrows H1 Loss; Shares Gain 1%

MT Newswires Live

PEGBIO CO-B (02565): Zou Xinglong Appointed as Joint Company Secretary, Authorized Representative and Legal Process Agent

PEGBIO CO-B (02565) Releases Interim Results with R&D Expenses of RMB 26.294 Million, Successfully Building Pipeline Matrix Covering 6 Drug Candidates for Chronic Diseases

Hong Kong Stock Alert | PEGBIO CO-B (02565) Surges Over 15% Again to New Listing High as GLP-1 Sector Gains Momentum, Company's Intrinsic Value Expected to Accelerate Release

HK Movers | Biotech Shares Soar. PegBio up 35%; Ascletis up 11%; TYK Medicines up 9%

Tiger Newspress

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/02565/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02565","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02565\",,,,,undefined,":{"symbol":"02565","market":"HK","secType":"STK","nameCN":"PEGBIO CO-B","latestPrice":59.45,"timestamp":1763102190918,"preClose":56.4,"halted":0,"volume":231500,"delay":0,"floatShares":279164339,"shares":386000000,"eps":-0.8455036641311525,"marketStatus":"Trading","change":3.05,"latestTime":"11-14 14:36:35","open":54.75,"high":60,"low":54.75,"amount":13637525,"amplitude":0.093085,"askPrice":59.45,"askSize":1500,"bidPrice":58.95,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":-0.6577970485684317,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1763107800000},"marketStatusCode":2,"adr":0,"listingDate":1748275200000,"exchange":"SEHK","adjPreClose":56.4,"openAndCloseTimeList":[[1763083800000,1763092800000],[1763096400000,1763107200000]],"volumeRatio":1.86215,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02565\",,,,,undefined,":{"symbol":"02565","floatShares":279164339,"roa":"-61.30%","roe":"-224.15%","lyrEps":-0.845504,"volumeRatio":1.86215,"shares":386000000,"dividePrice":0,"high":60,"amplitude":0.093085,"preClose":56.4,"low":54.75,"week52Low":8.68,"pbRate":"82.12","psRate":"-5408.82","week52High":62.25,"institutionHeld":0,"latestPrice":59.45,"eps":-0.8455036641311525,"divideRate":0,"volume":231500,"delay":0,"ttmEps":-0.6577970485684317,"open":54.75,"prevYearClose":15.6,"prevWeekClose":51.45,"prevMonthClose":60.1,"prevQuarterClose":54.2,"fiveDayClose":51.45,"twentyDayClose":52.6,"sixtyDayClose":32.1},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02565\",params:#limit:5,,,undefined,":[{"date":"2025-08-26","symbol":"02565","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02565\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02565\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":0,"sell":0,"strongSell":1,"meanLabel":"STRONG SELL","meanPercent":1,"analysts":1,"updateTime":1755100800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02565\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02565","date":"2025-11-13","current":-85.759169,"percent":0.033613,"low":-69.902193,"twenty":-60.85037,"median":-39.897335,"eighty":-12.881298,"high":-11.114373,"avg":-36.925867,"sd":21.929748,"marketCap":15744868719},"quantilePoints":[{"date":"2025-05-30","current":-12.743079,"twenty":-15.470266,"median":-13.542645,"eighty":-13.135794,"marketCap":3936746426},{"date":"2025-06-06","current":-11.987888,"twenty":-13.726785,"median":-12.740515,"eighty":-12.114178,"marketCap":3712892217},{"date":"2025-06-13","current":-11.23576,"twenty":-13.295707,"median":-12.114337,"eighty":-11.528404,"marketCap":3481318898},{"date":"2025-06-20","current":-11.30775,"twenty":-12.841258,"median":-11.963331,"eighty":-11.337793,"marketCap":3496757119},{"date":"2025-06-27","current":-12.421214,"twenty":-12.738977,"median":-11.541778,"eighty":-11.292079,"marketCap":3851836209},{"date":"2025-07-04","current":-13.963875,"twenty":-12.971799,"median":-11.987888,"eighty":-11.299391,"marketCap":4330421069},{"date":"2025-07-11","current":-13.604213,"twenty":-13.050401,"median":-12.199189,"eighty":-11.305737,"marketCap":4214634409},{"date":"2025-07-18","current":-16.956264,"twenty":-13.748078,"median":-12.438987,"eighty":-11.330282,"marketCap":5248995235},{"date":"2025-07-25","current":-19.006677,"twenty":-15.472199,"median":-12.742066,"eighty":-11.352726,"marketCap":5905119639},{"date":"2025-08-01","current":-19.199848,"twenty":-18.276271,"median":-12.906561,"eighty":-11.424474,"marketCap":5928276971},{"date":"2025-08-08","current":-20.51103,"twenty":-19.019895,"median":-13.05938,"eighty":-11.472546,"marketCap":6348968501},{"date":"2025-08-15","current":-39.959751,"twenty":-19.179784,"median":-13.542645,"eighty":-11.515029,"marketCap":12350577024},{"date":"2025-08-22","current":-41.864246,"twenty":-19.284777,"median":-13.964282,"eighty":-11.779976,"marketCap":12898633879},{"date":"2025-08-29","current":-41.44792,"twenty":-21.432837,"median":-14.946806,"eighty":-11.968242,"marketCap":10033166343},{"date":"2025-09-05","current":-50.678037,"twenty":-39.039264,"median":-17.018603,"eighty":-12.06328,"marketCap":12255314482},{"date":"2025-09-12","current":-58.538001,"twenty":-40.749762,"median":-18.438762,"eighty":-12.114019,"marketCap":14181548421},{"date":"2025-09-19","current":-57.311117,"twenty":-43.720929,"median":-18.952908,"eighty":-12.216159,"marketCap":13874467648},{"date":"2025-09-26","current":-63.587749,"twenty":-49.33228,"median":-19.070122,"eighty":-12.366345,"marketCap":15354038645},{"date":"2025-10-03","current":-60.149194,"twenty":-54.575673,"median":-19.16943,"eighty":-12.428323,"marketCap":14558420278},{"date":"2025-10-10","current":-60.121463,"twenty":-57.957283,"median":-19.199848,"eighty":-12.49878,"marketCap":14530503844},{"date":"2025-10-17","current":-60.168303,"twenty":-59.756564,"median":-19.2984,"eighty":-12.738571,"marketCap":14530503844},{"date":"2025-10-24","current":-61.301982,"twenty":-60.143648,"median":-20.51103,"eighty":-12.741458,"marketCap":14809668183},{"date":"2025-10-31","current":-69.345185,"twenty":-60.159469,"median":-22.018639,"eighty":-12.743079,"marketCap":16777776773},{"date":"2025-11-07","current":-59.401661,"twenty":-60.392128,"median":-34.33922,"eighty":-12.780248,"marketCap":14363005241},{"date":"2025-11-13","current":-64.932693,"twenty":-60.85037,"median":-39.897335,"eighty":-12.881298,"marketCap":15744868719}],"updateTime":1763079552773},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02565\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1104226063","title":"HK Movers | Biomedical Stocks Jump With CStone Pharmaceuticals up 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1104226063","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104226063?lang=en_us&edition=fundamental","pubTime":"2025-11-14 10:24","pubTimestamp":1763087071,"startTime":"0","endTime":"0","summary":"Biomedical stocks jumped in Hong Kong. CStone Pharmaceuticals rose 13%; Ascletis Pharma rose 11%; Sirnaomics rose 9%; Laekna rose 7%; PegBio Co rose 6%; Immunotech Biopharm rose 5%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","01672","02257","02105","06978","02616"],"gpt_icon":0},{"id":"1168411634","title":"HK Stock Movement | PEGBIO CO-B (02565) Surges Over 15% as GLP-1 Weight-Loss Drug Expands to Middle East and Africa","url":"https://stock-news.laohu8.com/highlight/detail?id=1168411634","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168411634?lang=en_us&edition=fundamental","pubTime":"2025-11-13 11:32","pubTimestamp":1763004736,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) saw its shares surge by more than 15% at one point during the trading session. As of press time, the stock was up 6.29%, trading at HK$56.65 with a turnover of HK$9.94 million....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4590","161726","BK4144","02565","BK1161","399441","GLP"],"gpt_icon":0},{"id":"1177976721","title":"PegBio (02565) Publishes Monthly Securities Return for October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1177976721","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177976721?lang=en_us&edition=fundamental","pubTime":"2025-11-05 17:29","pubTimestamp":1762334995,"startTime":"0","endTime":"0","summary":"PegBio Co., Ltd. (02565) published its monthly return on movements in securities for October 2025, confirming that the total registered share capital remained unchanged at RMB 385,955,532. The H...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"gpt_icon":0},{"id":"1162611094","title":"PegBio (2565) Announces Voluntary Dissolution of Shanghai Maiji and Director’s Information Update","url":"https://stock-news.laohu8.com/highlight/detail?id=1162611094","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162611094?lang=en_us&edition=fundamental","pubTime":"2025-11-04 00:34","pubTimestamp":1762187668,"startTime":"0","endTime":"0","summary":"PegBio Co., Ltd. (the Company, stock code: 2565) announced that on 28 October 2025, an application was filed to voluntarily dissolve its non-wholly-owned subsidiary, Shanghai Maiji Biotech Co., Ltd....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"gpt_icon":0},{"id":"1121128950","title":"HK Stock Movement | PEGBIO CO-B (02565) Surges Over 20% at Close to Hit New High, Secures Exclusive License for Diabetes Drug in Middle East & Africa","url":"https://stock-news.laohu8.com/highlight/detail?id=1121128950","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121128950?lang=en_us&edition=fundamental","pubTime":"2025-10-31 15:40","pubTimestamp":1761896419,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) surged over 20% in late trading, reaching a record high of HK$62.25. At the time of writing, the stock was up 16.51% at HK$60.3, with a turnover of HK$30.23 million. The company...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","161726","399441","BK1161"],"gpt_icon":0},{"id":"2574617638","title":"PegBio Proposes Exclusive License for Diabetes Mellitus Drug for UAE Pharma R&D Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2574617638","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574617638?lang=en_us&edition=fundamental","pubTime":"2025-10-10 20:23","pubTimestamp":1760099008,"startTime":"0","endTime":"0","summary":"PegBio (HKG:2565) is considering granting an exclusive license for Visepegenatide to UAE pharmaceutical R&D organization PDC FZ-LLC, a Friday Hong Kong bourse filing said.Under the terms of the non-bi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02565","BK1161","UAE"],"gpt_icon":0},{"id":"2574122047","title":"BRIEF-PegBio Says PDC Granted Exclusive License For Pb-119 In Middle East And Africa","url":"https://stock-news.laohu8.com/highlight/detail?id=2574122047","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574122047?lang=en_us&edition=fundamental","pubTime":"2025-10-10 18:28","pubTimestamp":1760092107,"startTime":"0","endTime":"0","summary":"BRIEF-PegBio Says PDC Granted Exclusive License For Pb-119 In Middle East And AfricaOct 10 (Reuters) - PegBio Co Ltd 2565.HK:PDC GRANTED EXCLUSIVE LICENSE FOR PB-119 IN MIDDLE EAST AND AFRICALICENSE I","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nFWN3VR1HK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","BK1161"],"gpt_icon":0},{"id":"1134302079","title":"PEGBIO CO-B (02565): Proposes to Grant Exclusive License for VISEPEGENATIDE (PB-119) in Middle East and Africa","url":"https://stock-news.laohu8.com/highlight/detail?id=1134302079","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134302079?lang=en_us&edition=fundamental","pubTime":"2025-10-10 17:07","pubTimestamp":1760087267,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) announced that the company has entered into a non-binding term sheet with PDC FZ-LLC, a United Arab Emirates-based entity, regarding the exclusive licensing of the company's...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161726","PB","IE00B64QTZ34.USD","399441","BK4211","BK1161","02565","IE00BLDYK493.USD"],"gpt_icon":0},{"id":"2574262241","title":"Pegbio Co Ltd Announces Proposed Exclusive License Agreement for Visepegenatide PB119 in Middle East and Africa","url":"https://stock-news.laohu8.com/highlight/detail?id=2574262241","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574262241?lang=en_us&edition=fundamental","pubTime":"2025-10-10 17:03","pubTimestamp":1760086998,"startTime":"0","endTime":"0","summary":"PegBio Co., Ltd. announced that it has entered into a non-binding term sheet with PDC FZ-LLC of the United Arab Emirates for the proposed grant of an exclusive license for Visepegenatide , a subcutaneous injectable GLP-1 agonist for the treatment of Type II Diabetes Mellitus and obesity management. Under the proposed terms, PDC will receive exclusive rights to develop, distribute, market, and commercialize PB-119 in the Middle East and Africa. The agreement is positioned as part of PegBio's global commercialization strategy for PB-119. The company noted that there is no guarantee that PB-119 will ultimately be successfully developed and marketed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original cont","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nNDL5n6V4C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","BK1161"],"gpt_icon":0},{"id":"2574126412","title":"Pegbio Co Ltd - Announces Non-Binding Term Sheet With Pdc Fz-Llc","url":"https://stock-news.laohu8.com/highlight/detail?id=2574126412","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574126412?lang=en_us&edition=fundamental","pubTime":"2025-10-10 17:01","pubTimestamp":1760086866,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nFWN3VQ1VZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02565"],"gpt_icon":0},{"id":"2574612610","title":"Pegbio Co Ltd - Pdc Granted Exclusive License for PB-119 in Middle East and Africa","url":"https://stock-news.laohu8.com/highlight/detail?id=2574612610","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574612610?lang=en_us&edition=fundamental","pubTime":"2025-10-10 17:00","pubTimestamp":1760086858,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nFWN3VR1HK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02565","BK1161"],"gpt_icon":0},{"id":"2574126102","title":"Pegbio Co Ltd - License Includes Regional Development and Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2574126102","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574126102?lang=en_us&edition=fundamental","pubTime":"2025-10-10 17:00","pubTimestamp":1760086858,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nFWN3VR1HK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02565"],"gpt_icon":0},{"id":"1198655515","title":"Hong Kong Stock Movement | PEGBIO CO-B (02565) Surges Over 5% in Morning Trading, Advanced Clinical Progress in GLP-1 Multi-Target Field with PB-718 as Key Pipeline Product","url":"https://stock-news.laohu8.com/highlight/detail?id=1198655515","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198655515?lang=en_us&edition=fundamental","pubTime":"2025-09-23 12:00","pubTimestamp":1758600029,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) surged over 5% in morning trading, with the stock having gained over 3.1 times since its listing. As of press time, the stock was up 5.25% to HK$54.15, with a trading volume of...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161726","BK4614","BK1161","399441","YANG","HSCEI","07226","GLP","02565","BK4144","BK4211","BK4590","PB"],"gpt_icon":1},{"id":"1162198525","title":"PEGBIO CO-B (02565): Major Milestone Breakthrough in MASH Treatment R&D Opens Up Hundred-Billion Valuation Growth Ceiling","url":"https://stock-news.laohu8.com/highlight/detail?id=1162198525","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162198525?lang=en_us&edition=fundamental","pubTime":"2025-09-04 17:07","pubTimestamp":1756976826,"startTime":"0","endTime":"0","summary":"In recent years, the global glucagon-like peptide-1 receptor agonist (GLP-1) drug sector has maintained intense momentum, with related markets experiencing accelerated expansion. GLP-1 drug sales...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["399441","02565","161726","BK1161"],"gpt_icon":0},{"id":"1129607367","title":"Hong Kong Stock Alert | PEGBIO CO-B (02565) Surges Over 7% to New High as PB-119 Registration Application Accepted, Domestic Commercialization Imminent","url":"https://stock-news.laohu8.com/highlight/detail?id=1129607367","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129607367?lang=en_us&edition=fundamental","pubTime":"2025-09-01 10:54","pubTimestamp":1756695264,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) climbed more than 7%, reaching a peak of HK$38.66 and setting a new listing high. At the time of reporting, the stock was up 5.84% at HK$38.04 with trading volume of HK$18.89...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161726","02565","PB","399441","BK1161","BK4211"],"gpt_icon":0},{"id":"2562796929","title":"PegBio Narrows H1 Loss; Shares Gain 1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562796929","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562796929?lang=en_us&edition=fundamental","pubTime":"2025-08-27 12:37","pubTimestamp":1756269423,"startTime":"0","endTime":"0","summary":"PegBio  reported a loss attributable to equity shareholders of the company of 93.62 million yuan for the first half of 2025, compared with a loss of 155.37 million yuan a year earlier, according to a Tuesday Hong Kong bourse filing.Shares of the biotechnology firm were up over 1% in Wednesday late-morning trade.Loss per share came in at 0.25 yuan, compared with 0.42 yuan in the prior-year period.Other net income was 178,000 yuan, compared with 4.05 million yuan a year earlier.The firm said it has no products approved for commercial sale and has not generated any revenue from product sales.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02565"],"gpt_icon":0},{"id":"1116016440","title":"PEGBIO CO-B (02565): Zou Xinglong Appointed as Joint Company Secretary, Authorized Representative and Legal Process Agent","url":"https://stock-news.laohu8.com/highlight/detail?id=1116016440","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116016440?lang=en_us&edition=fundamental","pubTime":"2025-08-26 21:31","pubTimestamp":1756215061,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) announced that Ms. Chen Wanmei has submitted her resignation from the positions of joint company secretary, authorized representative under Rule 3.05 of the Rules Governing the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","161726","399441","BK1161"],"gpt_icon":0},{"id":"1153985934","title":"PEGBIO CO-B (02565) Releases Interim Results with R&D Expenses of RMB 26.294 Million, Successfully Building Pipeline Matrix Covering 6 Drug Candidates for Chronic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=1153985934","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153985934?lang=en_us&edition=fundamental","pubTime":"2025-08-26 21:22","pubTimestamp":1756214539,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) announced its interim results for the six months ended June 30, 2025. The group recorded other net income of RMB 178,000 (all amounts in RMB), R&D expenses of RMB 26.294 million,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","161726","399441","BK1161"],"gpt_icon":0},{"id":"1149878412","title":"Hong Kong Stock Alert | PEGBIO CO-B (02565) Surges Over 15% Again to New Listing High as GLP-1 Sector Gains Momentum, Company's Intrinsic Value Expected to Accelerate Release","url":"https://stock-news.laohu8.com/highlight/detail?id=1149878412","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149878412?lang=en_us&edition=fundamental","pubTime":"2025-08-18 14:12","pubTimestamp":1755497540,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) surged over 15% again, reaching a high of HK$37 and setting a new listing record. As of press time, the stock was up 14.5% to HK$36.64 with a turnover of HK$25.9996 million. On...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"cbf47a4577f9edc070eedd7d841a6ced","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["399441","GLP","02565","BK4590","161726","BK1161","BK4144"],"gpt_icon":0},{"id":"1168554344","title":"HK Movers | Biotech Shares Soar. PegBio up 35%; Ascletis up 11%; TYK Medicines up 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168554344","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168554344?lang=en_us&edition=fundamental","pubTime":"2025-08-15 10:20","pubTimestamp":1755224445,"startTime":"0","endTime":"0","summary":"Hong Kong’s biotech stocks rose on Friday.PegBio rose 35%; Ascletis rose 11%; TYK Medicines rose 9%; Ab&B Bio-Tech, JW Therapeutics rose 5%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b596819316a65b7eebee6f2210b3d5a1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","02627","02410","02565"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":25,"code":"91000000","status":"200"}]}}